Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1956 1
1965 1
1968 1
1971 1
1972 1
1973 2
1974 1
1975 3
1976 5
1977 4
1978 6
1979 5
1980 3
1981 3
1982 1
1983 7
1984 5
1985 9
1986 9
1987 10
1988 9
1989 6
1990 7
1991 4
1992 9
1993 5
1994 18
1995 8
1996 7
1997 6
1998 4
1999 4
2000 10
2001 8
2002 7
2003 10
2004 6
2005 9
2006 13
2007 10
2008 8
2009 6
2010 9
2011 12
2012 15
2013 10
2014 6
2015 15
2016 14
2017 23
2018 26
2019 37
2020 16
2021 29
2022 21
2023 24
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

493 results

Results by year

Filters applied: . Clear all
Page 1
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, Yakushin S, Ishii T, Emoto K, Beattie S, Arora V, Gaich C, Rooney T, Schlichting D, Macias WL, de Bono S, Tanaka Y. Taylor PC, et al. N Engl J Med. 2017 Feb 16;376(7):652-662. doi: 10.1056/NEJMoa1608345. N Engl J Med. 2017. PMID: 28199814 Free article. Clinical Trial.
The Jak/STAT pathway: A focus on pain in rheumatoid arthritis.
Simon LS, Taylor PC, Choy EH, Sebba A, Quebe A, Knopp KL, Porreca F. Simon LS, et al. Among authors: taylor pc. Semin Arthritis Rheum. 2021 Feb;51(1):278-284. doi: 10.1016/j.semarthrit.2020.10.008. Epub 2020 Dec 18. Semin Arthritis Rheum. 2021. PMID: 33412435 Free article. Review.
Alterations in the gut microbiome implicate key taxa and metabolic pathways across inflammatory arthritis phenotypes.
Thompson KN, Bonham KS, Ilott NE, Britton GJ, Colmenero P, Bullers SJ, McIver LJ, Ma S, Nguyen LH, Filer A, Brough I, Pearson C, Moussa C, Kumar V, Lam LH, Jackson MA, Pawluk A; Inflammatory Arthritis Microbiome Consortium (IAMC) investigators group; Kiriakidis S, Taylor PC, Wedderburn LR, Marsden B, Young SP, Littman DR, Faith JJ, Pratt AG, Bowness P, Raza K, Powrie F, Huttenhower C; IAMC. Thompson KN, et al. Among authors: taylor pc. Sci Transl Med. 2023 Jul 26;15(706):eabn4722. doi: 10.1126/scitranslmed.abn4722. Epub 2023 Jul 26. Sci Transl Med. 2023. PMID: 37494472
Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes.
Lewis MJ, Barnes MR, Blighe K, Goldmann K, Rana S, Hackney JA, Ramamoorthi N, John CR, Watson DS, Kummerfeld SK, Hands R, Riahi S, Rocher-Ros V, Rivellese F, Humby F, Kelly S, Bombardieri M, Ng N, DiCicco M, van der Heijde D, Landewé R, van der Helm-van Mil A, Cauli A, McInnes IB, Buckley CD, Choy E, Taylor PC, Townsend MJ, Pitzalis C. Lewis MJ, et al. Among authors: taylor pc. Cell Rep. 2019 Aug 27;28(9):2455-2470.e5. doi: 10.1016/j.celrep.2019.07.091. Cell Rep. 2019. PMID: 31461658 Free PMC article.
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).
Fleischmann RM, van der Heijde D, Strand V, Atsumi T, McInnes IB, Takeuchi T, Taylor PC, Bracher M, Brooks D, Davies J, Goode C, Gupta A, Mukherjee S, O'Shea C, Saurigny D, Schifano LA, Shelton C, Smith JE, Wang M, Wang R, Watts S, Weinblatt ME. Fleischmann RM, et al. Among authors: taylor pc. Ann Rheum Dis. 2023 Dec;82(12):1516-1526. doi: 10.1136/ard-2023-224482. Epub 2023 Sep 12. Ann Rheum Dis. 2023. PMID: 37699654 Free PMC article. Clinical Trial.
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
Taylor PC, Takeuchi T, Burmester GR, Durez P, Smolen JS, Deberdt W, Issa M, Terres JR, Bello N, Winthrop KL. Taylor PC, et al. Ann Rheum Dis. 2022 Mar;81(3):335-343. doi: 10.1136/annrheumdis-2021-221276. Epub 2021 Oct 27. Ann Rheum Dis. 2022. PMID: 34706874 Free PMC article.
493 results